Huang SM - Search Results

1

Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.

Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL; Kidney Health Initiative. Nolin TD, et al. Among authors: huang sm. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):159-64. doi: 10.2215/CJN.05630614. Epub 2014 Sep 4. Clin J Am Soc Nephrol. 2015. PMID: 25189923 Free PMC article.

2

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM. Zhao P, et al. Among authors: huang sm. J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196. J Clin Pharmacol. 2009. PMID: 19246732

3

Predicting drug-drug interactions: an FDA perspective.

Zhang L, Zhang YD, Zhao P, Huang SM. Zhang L, et al. Among authors: huang sm. AAPS J. 2009 Jun;11(2):300-6. doi: 10.1208/s12248-009-9106-3. Epub 2009 May 6. AAPS J. 2009. PMID: 19418230 Free PMC article. Review.

4

Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions.

Zhang L, Zhang Y, Huang SM. Zhang L, et al. Among authors: huang sm. Mol Pharm. 2009 Nov-Dec;6(6):1766-74. doi: 10.1021/mp900132e. Mol Pharm. 2009. PMID: 19839641 Review.

5

Drug interactions evaluation: an integrated part of risk assessment of therapeutics.

Zhang L, Reynolds KS, Zhao P, Huang SM. Zhang L, et al. Among authors: huang sm. Toxicol Appl Pharmacol. 2010 Mar 1;243(2):134-45. doi: 10.1016/j.taap.2009.12.016. Epub 2010 Jan 4. Toxicol Appl Pharmacol. 2010. PMID: 20045016 Review.

6

Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.

Zineh I, Huang SM. Zineh I, et al. Among authors: huang sm. Biomark Med. 2011 Dec;5(6):705-13. doi: 10.2217/bmm.11.90. Biomark Med. 2011. PMID: 22103607 Review.

7

Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.

Zhang L, Xu N, Xiao S, Arya V, Zhao P, Lesko LJ, Huang SM. Zhang L, et al. Among authors: huang sm. J Clin Pharmacol. 2012 Jan;52(1 Suppl):79S-90S. doi: 10.1177/0091270011415410. J Clin Pharmacol. 2012. PMID: 22232757

8

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson AJ Jr, Sugiyama Y, Pang KS, Reynolds KS, Abernethy DR, Zhang L, Lesko LJ, Huang SM. Zhao P, et al. Among authors: huang sm. J Clin Pharmacol. 2012 Jan;52(1 Suppl):91S-108S. doi: 10.1177/0091270011415528. J Clin Pharmacol. 2012. PMID: 22232759

9

A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment.

Park EJ, Wu K, Mi Z, Dong T, Lawrence JP, Ko CW, Huang SM, Zhang L, Crentsil V, Zhang J, Xu NN. Park EJ, et al. Among authors: huang sm. Ann Pharmacother. 2012 Sep;46(9):1174-87. doi: 10.1345/aph.1Q757. Epub 2012 Aug 28. Ann Pharmacother. 2012. PMID: 22932303

10

The utility of modeling and simulation in drug development and regulatory review.

Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I. Huang SM, et al. J Pharm Sci. 2013 Sep;102(9):2912-23. doi: 10.1002/jps.23570. Epub 2013 May 24. J Pharm Sci. 2013. PMID: 23712632 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,230 results

Search Page